{"id":745496,"date":"2017-09-10T07:45:00","date_gmt":"2017-09-10T07:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/"},"modified":"2025-11-07T01:26:17","modified_gmt":"2025-11-07T06:26:17","slug":"mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/","title":{"rendered":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure"},"content":{"rendered":"<p class=\"bwalignc\">       Updated Data from Phase 3 KEYNOTE-045 Trial to Be Presented at ESMO        2017 Congress     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced updated results from the phase 3 KEYNOTE-045 trial<br \/>\n      evaluating KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1<br \/>\n      therapy, in patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma (a type of bladder cancer) with disease progression on or<br \/>\n      after platinum-containing chemotherapy (post-platinum failure). Updated<br \/>\n      data show that with median follow-up of 22.5 months, KEYTRUDA continues<br \/>\n      to demonstrate an overall survival (OS) benefit over investigator\u2019s<br \/>\n      choice of paclitaxel, docetaxel or vinflunine as a second-line therapy,<br \/>\n      post-platinum failure, regardless of PD-L1 expression (HR, 0.70 [95% CI,<br \/>\n      0.57-0.86], p=0.0003). Findings are being presented at the European<br \/>\n      Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, on<br \/>\n      Sunday, Sept. 10 (poster from 2:45 \u2013 4:15 p.m. CEST; discussion: 3:15 \u2013<br \/>\n      3:45 p.m. CEST) (Location: Cordoba Auditorium) (Abstract #LBA37_PR).\n    <\/p>\n<p>\n      \u201cThese data at ESMO provide further insights and greater understanding<br \/>\n      in using KEYTRUDA in select second-line advanced urothelial carcinoma<br \/>\n      treatment settings, and importantly, demonstrate an overall survival<br \/>\n      advantage with KEYTRUDA compared to standard chemotherapy agents<br \/>\n      vinflunine, docetaxel and paclitaxel, which are common in clinical<br \/>\n      practice for the treatment of this disease,\u201d said professor Ronald de<br \/>\n      Wit, M.D., Ph.D., group leader experimental systemic therapy of<br \/>\n      urogenital cancers, Erasmus MC Cancer Institute. \u201cFor previously treated<br \/>\n      patients, post-platinum failure, these findings are also encouraging as<br \/>\n      they show an overall survival benefit regardless of PD-L1 status or<br \/>\n      choice of commonly used chemotherapy.\u201d\n    <\/p>\n<p>\n      \u201cWith nearly two years follow-up, these updated phase 3 data continue to<br \/>\n      show an overall survival benefit with KEYTRUDA in patients with advanced<br \/>\n      urothelial carcinoma whose cancer has progressed after receiving<br \/>\n      previous treatment for their disease,\u201d said Dr. Roger Dansey, senior<br \/>\n      vice president and therapeutic area head, oncology late-stage<br \/>\n      development, Merck Research Laboratories. \u201cWe are pleased that, with the<br \/>\n      approval in the U.S. and recent approval of KEYTRUDA in the EU, more<br \/>\n      patients now have an important treatment option available to them.\u201d\n    <\/p>\n<p>\n      Currently, Merck also has the largest immuno-oncology clinical<br \/>\n      development program in bladder cancer, with 29 trials underway involving<br \/>\n      KEYTRUDA (pembrolizumab) as monotherapy and in combination, including<br \/>\n      four registration-enabling studies.\n    <\/p>\n<p>\n      <b>Data in Second-Line Post-Platinum Failure Patients, KEYNOTE-045<\/b>\n    <\/p>\n<p>\n      KEYNOTE-045 is an open-label, randomized phase 3 trial of KEYTRUDA<br \/>\n      compared to investigator\u2019s choice of chemotherapy (paclitaxel, docetaxel<br \/>\n      or vinflunine) in patients with locally advanced or metastatic<br \/>\n      urothelial cancer with disease progression on or after<br \/>\n      platinum-containing chemotherapy. The trial was prematurely stopped<br \/>\n      after a pre-planned interim analysis demonstrated significantly longer<br \/>\n      OS with KEYTRUDA compared to chemotherapy (median follow-up, 14.1<br \/>\n      months). Efficacy was assessed in the overall study population (n=542),<br \/>\n      as well as in patients with PD-L1 expression \u2013 defined as a combined<br \/>\n      positive score of 10 or more (CPS \u226510) (KEYTRUDA arm: n=74\/270;<br \/>\n      chemotherapy arm; n=90\/272) (additional details on the trial design are<br \/>\n      provided below).\n    <\/p>\n<p>\n      Data presented at ESMO (Abstract #LBA37_PR) include four months of<br \/>\n      additional follow-up (data cut-off, May 19, 2017; median follow up, 22.5<br \/>\n      months) and continue to show a superior OS advantage with KEYTRUDA<br \/>\n      compared to chemotherapy in the second-line setting, regardless of PD-L1<br \/>\n      expression. In the overall study population, data show a 30 percent<br \/>\n      reduction in the risk of death with KEYTRUDA (HR, 0.70 [95% CI,<br \/>\n      0.57-0.86], p=0.0003), the median OS was 10.3 months with KEYTRUDA (95%<br \/>\n      CI, 8.0-12.3) and 7.4 months with chemotherapy (95% CI, 6.3-8.3), and<br \/>\n      the 18-month OS rate was 33.2 percent with KEYTRUDA compared to 19.7<br \/>\n      percent with chemotherapy. Analysis of OS based on PD-L1 expression show<br \/>\n      a 42 percent reduction in the risk of death with KEYTRUDA (HR, 0.58 [95%<br \/>\n      CI, 0.39-0.86], p=0.0029) in patients whose tumors expressed PD-L1 (CPS<br \/>\n      \u226510), the median OS was 8.0 months with KEYTRUDA (95% CI, 5.0-12.3) and<br \/>\n      5.2 months with chemotherapy (95% CI, 4.2-7.5), and the 18-month OS rate<br \/>\n      was 30.0 percent with KEYTRUDA compared to 16.9 percent with<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      As previously reported, there was no significant difference in<br \/>\n      progression-free-survival (PFS) between treatment arms in the overall<br \/>\n      study population (HR, 0.96 [95% CI, 0.79-1.16], p=0.32). The median PFS<br \/>\n      was 2.1 months with KEYTRUDA (95% CI, 2.0-2.2) and 3.3 months with<br \/>\n      chemotherapy (95% CI, 2.4-3.5); the 18-month PFS rate was 15.3 percent<br \/>\n      with KEYTRUDA (pembrolizumab) compared to 4.8 percent with chemotherapy.<br \/>\n      In patients whose tumors expressed PD-L1 (CPS \u226510), the median PFS was<br \/>\n      2.1 months with KEYTRUDA (95% CI, 1.9-2.1) and 3.2 months with<br \/>\n      chemotherapy (95% CI, 2.2-3.5); the 18-month PFS rate was 16.3 percent<br \/>\n      with KEYTRUDA compared to 5.3 percent with chemotherapy (HR, 0.93 [95%<br \/>\n      CI, 0.65-1.33], p=0.32).\n    <\/p>\n<p>\n      Analyses of the secondary endpoints showed nearly double the overall<br \/>\n      response rate (ORR) with KEYTRUDA compared to chemotherapy in the<br \/>\n      overall study population, with an ORR of 21.1 percent in the KEYTRUDA<br \/>\n      arm (complete response rate (CR) of 7.8 percent and a partial response<br \/>\n      rate (PR) of 13.3 percent) and 11.0 percent in the chemotherapy arm (CR<br \/>\n      of 2.9 percent and a PR of 8.1 percent). The median time to response was<br \/>\n      2.1 months in both treatment arms; 57.9 percent of responses in the<br \/>\n      KEYTRUDA arm were ongoing at the time of analysis compared to 20.0<br \/>\n      percent in the chemotherapy arm. Median duration of response in patients<br \/>\n      with partial or complete responses had not yet been reached in the<br \/>\n      KEYTRUDA arm at the time of analysis (range: 1.6+ to 24.6+) with 67.0<br \/>\n      percent of responses ongoing at 12 months (calculated per Kaplan-Meier<br \/>\n      curve); in the chemotherapy arm, the median duration of response was 4.4<br \/>\n      months (range: 1.4+ to 24.0+) with 35.0 percent of responses ongoing at<br \/>\n      12 months (calculated per Kaplan-Meier curve).\n    <\/p>\n<p>\n      In patients whose tumors expressed PD-L1, the ORR was 20.3 percent in<br \/>\n      the KEYTRUDA arm (CR of 6.8 percent and a PR of 13.5 percent) and 6.7<br \/>\n      percent in the chemotherapy arm (CR of 2.2 percent and a PR of 4.4<br \/>\n      percent). The median time to response was 2.0 months in the KEYTRUDA arm<br \/>\n      and 2.1 months in the chemotherapy arm; 73.3 percent of responses in the<br \/>\n      KEYTRUDA arm were ongoing at the time of analysis compared to 33.3<br \/>\n      percent in the chemotherapy arm. The median duration of response in<br \/>\n      patients with partial or complete responses had not yet been reached in<br \/>\n      the KEYTRUDA arm at the time of analysis (range: 1.6+ to 23.5+) with<br \/>\n      77.0 percent of responses ongoing at 12 months (calculated per<br \/>\n      Kaplan-Meier curve); in the chemotherapy arm, the median duration of<br \/>\n      response was 4.4 months (range: 1.5+ to 20.8+) with 40.0 percent of<br \/>\n      responses ongoing at 12 months (calculated per Kaplan-Meier curve).\n    <\/p>\n<p>\n      A second abstract including a subgroup analysis from KEYNOTE-045<br \/>\n      (Abstract #851PD) was also accepted as a poster at ESMO and provides<br \/>\n      greater insight into the OS advantage with KEYTRUDA compared to the<br \/>\n      individual chemotherapy agents. The retrospective analysis showed a 27<br \/>\n      percent reduction in the risk of death versus paclitaxel (HR, 0.73 [95%<br \/>\n      CI, 0.55-0.96]), a 21 percent reduction in the risk of death versus<br \/>\n      docetaxel (HR, 0.79 [95% CI, 0.59-1.07]), and a 35 percent reduction in<br \/>\n      the risk of death versus vinflunine (HR, 0.65 [95% CI, 0.49-0.87]). No<br \/>\n      statistically significant difference in PFS was seen between KEYTRUDA<br \/>\n      and each chemotherapy agent. Analyses of the secondary endpoints showed<br \/>\n      an ORR of 11.9 percent, 6.0 percent, and 17.2 percent with paclitaxel,<br \/>\n      docetaxel, and vinflunine, respectively, compared to 21.1 percent in the<br \/>\n      KEYTRUDA (pembrolizumab) arm.\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA was consistent with that observed in<br \/>\n      previously reported studies. Treatment-related adverse events (TRAEs) of<br \/>\n      any grade occurred in 62.0 percent in the KEYTRUDA arm and 90.6 percent<br \/>\n      in the chemotherapy arm. Grade 3 or higher TRAEs occurred in 16.5<br \/>\n      percent and 50.2 percent of KEYTRUDA and chemotherapy patients,<br \/>\n      respectively. Immune-mediated adverse events occurred in 19.5 percent of<br \/>\n      patients in the KEYTRUDA arm and 7.5 percent in the chemotherapy arm.<br \/>\n      The discontinuation rate due to treatment-related adverse events was 7.1<br \/>\n      percent of patients in the KEYTRUDA arm and 12.5 percent of patients in<br \/>\n      the chemotherapy arm. Deaths due to treatment-related adverse events<br \/>\n      occurred in four patients treated with KEYTRUDA, one patient treated<br \/>\n      with paclitaxel, and three patients treated with vinflunine.\n    <\/p>\n<p>\n      <b>About KEYNOTE-045<\/b>\n    <\/p>\n<p>\n      In KEYNOTE-045, patients were randomized to receive either KEYTRUDA 200<br \/>\n      mg every three weeks (n=270) or investigator\u2019s choice of any of the<br \/>\n      following chemotherapy regimens, all given intravenously, every three<br \/>\n      weeks (n=272): paclitaxel 175 mg\/m<sup>2<\/sup>, docetaxel 75 mg\/m<sup>2<\/sup>,<br \/>\n      or vinflunine 320 mg\/m<sup>2<\/sup>. The dual primary endpoints were OS<br \/>\n      and PFS, as assessed by blinded independent central review (BICR) per<br \/>\n      RECIST (Response Evaluation Criteria in Solid Tumors) v1.1; key<br \/>\n      secondary endpoints included ORR, as assessed by BICR per RECIST 1.1,<br \/>\n      duration of response and safety. Efficacy was assessed in all patients,<br \/>\n      as well as in patients with PD-L1 expression.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 550 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of adult and<br \/>\n      pediatric patients with refractory classical Hodgkin lymphoma (cHL), or<br \/>\n      who have relapsed after three or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In adults with cHL,<br \/>\n      KEYTRUDA is administered at a fixed dose of 200 mg every three weeks<br \/>\n      until disease progression or unacceptable toxicity, or up to 24 months<br \/>\n      in patients without disease progression. In pediatric patients with cHL,<br \/>\n      KEYTRUDA is administered at a dose of 2 mg\/kg (up to a maximum of 200<br \/>\n      mg) every three weeks until disease progression or unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA (pembrolizumab) in pediatric patients with<br \/>\n      MSI-H central nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause thyroid disorders, including<br \/>\n      hyperthyroidism, hypothyroidism, and thyroiditis. Hyperthyroidism<br \/>\n      occurred in 96 (3.4%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.8%) and 3 (0.1%) hyperthyroidism. Hypothyroidism occurred in<br \/>\n      237 (8.5%) of 2799 patients receiving KEYTRUDA, including Grade 2 (6.2%)<br \/>\n      and 3 (0.1%) hypothyroidism. The incidence of new or worsening<br \/>\n      hypothyroidism was higher in patients with HNSCC, occurring in 28 (15%)<br \/>\n      of 192 patients with HNSCC, including Grade 3 (0.5%) hypothyroidism.<br \/>\n      Thyroiditis occurred in 16 (0.6%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 2 (0.3%) thyroiditis. Monitor patients for changes in<br \/>\n      thyroid function (at the start of treatment, periodically during<br \/>\n      treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs and symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA<br \/>\n      (pembrolizumab) for any Grade 3 immune-mediated adverse reaction that<br \/>\n      recurs and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. In<br \/>\n      addition, myelitis and myocarditis were reported in other clinical<br \/>\n      trials, including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA (pembrolizumab) occurred in 21% of patients; the most common<br \/>\n      (\u22651%) was diarrhea (2.5%). The most common adverse reactions with<br \/>\n      KEYTRUDA vs ipilimumab were fatigue (28% vs 28%), diarrhea (26% with<br \/>\n      KEYTRUDA), rash (24% vs 23%), and nausea (21% with KEYTRUDA).<br \/>\n      Corresponding incidence rates are listed for ipilimumab only for those<br \/>\n      adverse reactions that occurred at the same or lower rate than with<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of<br \/>\n      682 patients with metastatic NSCLC. The most common adverse event<br \/>\n      resulting in permanent discontinuation of KEYTRUDA was pneumonitis<br \/>\n      (1.8%). Adverse reactions leading to interruption of KEYTRUDA occurred<br \/>\n      in 23% of patients; the most common (\u22651%) were diarrhea (1%), fatigue<br \/>\n      (1.3%), pneumonia (1%), liver enzyme elevation (1.2%), decreased<br \/>\n      appetite (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      When KEYTRUDA was administered in combination with carboplatin and<br \/>\n      pemetrexed (carbo\/pem), KEYTRUDA was discontinued in 10% of 59 patients.<br \/>\n      The most common adverse reaction resulting in discontinuation of<br \/>\n      KEYTRUDA (\u22652%) was acute kidney injury (3.4%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 39% of patients; the most common<br \/>\n      (\u22652%) were fatigue (8%), neutrophil count decreased (8%), anemia (5%),<br \/>\n      dyspnea (3.4%), and pneumonitis (3.4%).The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA compared to carbo\/pem alone were fatigue (71% vs<br \/>\n      50%), nausea (68% vs 56%), constipation (51% vs 37%), rash (42% vs 21%),<br \/>\n      vomiting (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs 23%),<br \/>\n      decreased appetite (31% vs 23%), headache (31% vs 16%), cough (24% vs<br \/>\n      18%), dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs<br \/>\n      4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia<br \/>\n      (20% vs 3.2%), upper respiratory tract infection (20% vs 3.2%), and<br \/>\n      arthralgia (15% vs 24%). This study was not designed to demonstrate a<br \/>\n      statistically significant difference in adverse reaction rates for<br \/>\n      KEYTRUDA as compared to carbo\/pem alone for any specified adverse<br \/>\n      reaction.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL, and treatment was interrupted due to adverse<br \/>\n      reactions in 26% of patients. Fifteen percent (15%) of patients had an<br \/>\n      adverse reaction requiring systemic corticosteroid therapy. Serious<br \/>\n      adverse reactions occurred in 16% of patients. The most frequent serious<br \/>\n      adverse reactions (\u22651%) included pneumonia, pneumonitis, pyrexia,<br \/>\n      dyspnea, GVHD, and herpes zoster. Two patients died from causes other<br \/>\n      than disease progression; one from GVHD after subsequent allogeneic HSCT<br \/>\n      and one from septic shock. The most common adverse reactions (occurring<br \/>\n      in \u226520% of patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reactions (in\u226520% of patients) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%). Eighteen patients<br \/>\n      (5%) died from causes other than disease progression. Five patients<br \/>\n      (1.4%) who were treated with KEYTRUDA experienced sepsis which led to<br \/>\n      death, and 3 patients (0.8%) experienced pneumonia which led to death.<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 22% of<br \/>\n      patients; the most common (\u22651%) were liver enzyme increase, diarrhea,<br \/>\n      urinary tract infection, acute kidney injury, fatigue, joint pain, and<br \/>\n      pneumonia. Serious adverse reactions occurred in 42% of patients, the<br \/>\n      most frequent (\u22652%) of which were urinary tract infection, hematuria,<br \/>\n      acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (20%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated<br \/>\n      patients, the most frequent (\u22652%) of which were urinary tract infection,<br \/>\n      pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. Efficacy for<br \/>\n      pediatric patients was extrapolated from the results in the adult cHL<br \/>\n      population. In a study of 40 pediatric patients with advanced melanoma,<br \/>\n      PD-L1\u2013positive advanced, relapsed, or refractory solid tumors or<br \/>\n      lymphoma, patients were treated with KEYTRUDA (pembrolizumab) for a<br \/>\n      median of 43 days (range 1-414 days), with 24 patients (60%) receiving<br \/>\n      treatment for 42 days or more. The safety profile in pediatric patients<br \/>\n      was similar to that seen in adults treated with KEYTRUDA. Toxicities<br \/>\n      that occurred at a higher rate (\u226515% difference) in these patients when<br \/>\n      compared to adults under 65 years of age were fatigue (45%), vomiting<br \/>\n      (38%), abdominal pain (28%), hypertransaminasemia (28%), and<br \/>\n      hyponatremia (18%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=ee2f4c9ce05486f40f1f15b988137f98\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=45d7388851cbed7ff07505d2d05e1ef7\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n<span class=\"bwuline\"><br \/>\n      <\/span>and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=06cff45ccd2faab06431728126036ff9\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=a6aad337da5a314da2619f4e90c9f891\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=37ae858d2198162f317056170f763173\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=3cc20d6c6880bd60b777abc9482712b7\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=5a2f6fcbf36c8cd3a09af4400c70f64e\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=60cc3d6fa9c15a25dfef30f50a8fa5b5\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=a29afc5819ef9c02bd4169c6aac4038d\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<br \/>\n      Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51681198&amp;newsitemid=20170910005046&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=d369ac427ff6b67b8c70f7d6665a06e9\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170910005046r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-740-6132<br \/>or<br \/>Investors<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated results from the phase 3 KEYNOTE-045 trial evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) with disease progression on or after platinum-containing chemotherapy (post-platinum failure). Updated data show that with median follow-up of 22.5 months, KEYTRUDA continues to demonstrate an overall survival (OS) benefit over investigator\u2019s choice of paclitaxel, docetaxel or vinflunine as a second-line therapy, post-platinum failure, regardless of PD-L1 expression (HR, 0.70 [95% CI, 0.57-0.86], p=0.0003). Findings are being presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, on Sunday, Sept. 10 (poster from 2:45 \u2013 4:15 p.m. CEST; discussion: 3:15 \u2013 3:45 p.m. CEST) (Location: Cordoba Auditorium) (Abstract #LBA37_PR). \u201cThese data at ESMO<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745496","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated results from the phase 3 KEYNOTE-045 trial evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) with disease progression on or after platinum-containing chemotherapy (post-platinum failure). Updated data show that with median follow-up of 22.5 months, KEYTRUDA continues to demonstrate an overall survival (OS) benefit over investigator\u2019s choice of paclitaxel, docetaxel or vinflunine as a second-line therapy, post-platinum failure, regardless of PD-L1 expression (HR, 0.70 [95% CI, 0.57-0.86], p=0.0003). Findings are being presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, on Sunday, Sept. 10 (poster from 2:45 \u2013 4:15 p.m. CEST; discussion: 3:15 \u2013 3:45 p.m. CEST) (Location: Cordoba Auditorium) (Abstract #LBA37_PR). \u201cThese data at ESMO\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"24 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\\\/\",\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-09-10T07:45:00+00:00\",\"dateModified\":\"2025-11-07T06:26:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated results from the phase 3 KEYNOTE-045 trial evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) with disease progression on or after platinum-containing chemotherapy (post-platinum failure). Updated data show that with median follow-up of 22.5 months, KEYTRUDA continues to demonstrate an overall survival (OS) benefit over investigator\u2019s choice of paclitaxel, docetaxel or vinflunine as a second-line therapy, post-platinum failure, regardless of PD-L1 expression (HR, 0.70 [95% CI, 0.57-0.86], p=0.0003). Findings are being presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, on Sunday, Sept. 10 (poster from 2:45 \u2013 4:15 p.m. CEST; discussion: 3:15 \u2013 3:45 p.m. CEST) (Location: Cordoba Auditorium) (Abstract #LBA37_PR). \u201cThese data at ESMO","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:17+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"24 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/","name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-09-10T07:45:00+00:00","dateModified":"2025-11-07T06:26:17+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-continues-to-show-overall-survival-benefit-over-chemotherapy-with-nearly-two-years-follow-up-in-previously-treated-patients-with-advanced-urothelial-carc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"76f4f28d-ff0c-463b-a965-d712ab285b42","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-KEYTRUDA-pembrolizumab-Continues-to-Show-Overall-Survival-Benefit-Over-Chemotherapy-with-Nearly-Two-Years-Follow-Up-in-Previou-YMDBU.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745496\/revisions"}],"predecessor-version":[{"id":3674853,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745496\/revisions\/3674853"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745496"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}